Cargando…
Lymphohistocytic myocarditis after Ad26.COV2.S viral vector COVID-19 vaccination
Autores principales: | Ujueta, Francisco, Azimi, Roshanak, Lozier, Matthew R., Poppiti, Robert, Ciment, Ari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421108/ https://www.ncbi.nlm.nih.gov/pubmed/34514078 http://dx.doi.org/10.1016/j.ijcha.2021.100869 |
Ejemplares similares
-
Multiple drugs: Lymphohistocytic myocarditis and lack of efficacy: case report
Publicado: (2022) -
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
por: Muir, Kate-Lynn, et al.
Publicado: (2021) -
Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study
por: Takuva, Simbarashe, et al.
Publicado: (2021) -
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022) -
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
por: Sadoff, Jerald, et al.
Publicado: (2021)